Lates News

According to the AI news flash of Every Economy, on September 25, Open Source Securities issued a research report giving a "buy" rating to Front Bio (688221.SH). The reasons for the rating mainly include: 1) Front Bio's forward-looking layout of small nucleic acid technology, deepening innovation leading long-term development; 2) Forward-looking layout of small nucleic acid field for multiple indications, self-developed ACORDE delivery vector; 3) Grasping the clinical pain points of HIV to provide a complete long-acting treatment plan, expanding contributions to performance in generic drugs and equipment. (Daily Economic News)